Skip To Main Content
Suying Lu on Muck Rack

Suying Lu

As seen in: Nature, Wiley Online Library, Journal of Translational Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Suying

Contact Suying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Lorlatinib monotherapy or combination therapy in anaplastic lymphoma kinase–driven high-risk neuroblastoma

|
By Weiji Xie, Yu Zhang, Suying Lu, Feifei Sun, Jia Zhu, Yi Que, Junting Huang, Mengjia Song, Zijun Zhen, Juan Wang, Yizhuo Zhang
| Nature Verified
Abstract This study evaluated the clinical efficacy and safety of lorlatinib in 25 patients with anaplastic lymphoma kinase (ALK) -driven neuroblastoma. Among 17 evaluable patients, the objective response rate (ORR) was 64.7% (11/17). All six newly diagnosed high-risk patients who received lorlatinib in combination with induction chemotherapy achieved an objective response.
Open in Who Shared Issue with article?

Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for point of care clinical application

|
By Cielo León, Suying Lu, David Duplat, Paula Benitez-Bolivar
| PLOS
Loading metrics Open Access Peer-reviewed Research Article Abstract Continued waves, new variants, and limited vaccine deployment mean that SARS-CoV-2 tests remain vital to constrain the coronavirus disease 2019 (COVID-19) pandemic. Affordable, point-of-care (PoC) tests allow rapid screening in non-medical settings. Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) is an appealing approach. A crucial step is to optimize testing in low/medium resource settings.
Open in Who Shared Issue with article?
See all 2 articles